2017 February

The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.

Ali Maawy, MD, and Patrick M. Boland, MD, provide a brief review of the immune environment of colorectal cancer (CRC) and recently reported studies of immunotherapy in CRC.

This manuscript focuses on the latest clinical developments of newer generation selective CDK inhibitors in lung cancer.

Results from the phase I portion of the first trial testing axicabtagene ciloleucel, an autologous CD3ζ/CD28-based CAR T-cell therapy, indicate that the regimen can safely be administered and lead to durable CR after more than 12 months in refractory diffuse large B-cell lymphoma.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that acquired resistance to checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.